Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
…, FR Appelbaum, T Büchner, AK Burnett… - Blood, The Journal …, 2010 - ashpublications.org
In 2003, an international working group last reported on recommendations for diagnosis,
response assessment, and treatment outcomes in acute myeloid leukemia (AML). Since that …
response assessment, and treatment outcomes in acute myeloid leukemia (AML). Since that …
The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial
…, J Rees, I Hann, R Stevens, A Burnett… - Blood, The Journal …, 1998 - ashpublications.org
Cytogenetics is considered one of the most valuable prognostic determinants in acute myeloid
leukemia (AML). However, many studies on which this assertion is based were limited by …
leukemia (AML). However, many studies on which this assertion is based were limited by …
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 …
…, K Wheatley, CJ Harrison, AK Burnett… - Blood, The Journal …, 2010 - ashpublications.org
Diagnostic karyotype provides the framework for risk-stratification schemes in acute myeloid
leukemia (AML); however, the prognostic significance of many rare recurring cytogenetic …
leukemia (AML); however, the prognostic significance of many rare recurring cytogenetic …
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and …
…, K Wheatley, DT Bowen, AK Burnett… - Blood, The Journal …, 2001 - ashpublications.org
In acute myeloid leukemia (AML), further prognostic determinants are required in addition to
cytogenetics to predict patients at increased risk of relapse. Recent studies have indicated …
cytogenetics to predict patients at increased risk of relapse. Recent studies have indicated …
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
…, O Mirguet, K Doehner, R Delwel, AK Burnett… - Nature, 2011 - nature.com
Recurrent chromosomal translocations involving the mixed lineage leukaemia (MLL) gene
initiate aggressive forms of leukaemia, which are often refractory to conventional therapies 1 . …
initiate aggressive forms of leukaemia, which are often refractory to conventional therapies 1 . …
Acute myeloid leukemia
…, JR Downing, A Burnett - New England Journal of …, 1999 - Mass Medical Soc
Acute myeloid leukemia (AML) is characterized by an increase in the number of myeloid
cells in the marrow and an arrest in their maturation, frequently resulting in hematopoietic …
cells in the marrow and an arrest in their maturation, frequently resulting in hematopoietic …
The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United …
…, CJ Harrison, K Wheatley, AK Burnett… - Blood, The Journal …, 2001 - ashpublications.org
Acute myeloid leukemia (AML) in older adults carries a poor prognosis, and the optimum
treatment remains to be determined. In younger patients, treatment stratification is frequently …
treatment remains to be determined. In younger patients, treatment stratification is frequently …
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
…, T Büchner, H Döhner, AK Burnett… - Blood, The Journal …, 2009 - ashpublications.org
The introduction of all-trans retinoic acid (ATRA) and, more recently, arsenic trioxide (ATO)
into the therapy of acute promyelocytic leukemia (APL) has revolutionized the management …
into the therapy of acute promyelocytic leukemia (APL) has revolutionized the management …
Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial
AK Burnett, RK Hills, D Milligan, L Kjeldsen… - Journal of clinical …, 2011 - ascopubs.org
Purpose Antibody-directed chemotherapy for acute myeloid leukemia (AML) may permit more
treatment to be administered without escalating toxicity. Gemtuzumab ozogamicin (GO) is …
treatment to be administered without escalating toxicity. Gemtuzumab ozogamicin (GO) is …
A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in …
AK Burnett, D Milligan, AG Prentice… - … Journal of the …, 2007 - Wiley Online Library
BACKGROUND The survival of older patients with acute myeloid leukemia has not improved.
Few clinical trials have been available for older patients who are not considered fit for an …
Few clinical trials have been available for older patients who are not considered fit for an …